A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma

• Sponsor: Medical University of South Carolina (Other)
• Overall Status: Completed
• CT.gov ID: NCT01593748
• Collaborator: Novartis (Industry)
• Enrollment: 90
• Locations: 8
• Arms: 2
• Actual Duration (Months): 78.9
• Patients Per Site: 11.3
• Patients Per Site Per Month: 0.1

Study Details

Study Description

Brief Summary

This study is for adult subjects with advanced tissue sarcoma. The study involves the drugs Pazopanib (Votrient), Gemcitabine (Gemzar), and Docetaxel (Taxotere). The purpose of this study is to test the effectiveness and safety of Gemcitabine and Pazopanib compared with Gemcitabine and Docetaxel in participants with soft tissue sarcoma.

Condition or Disease	Intervention/Treatment	Phase
Sarcoma	Drug: Gemcitabine and Pazopanib; Drug: Gemcitabine and Docetaxel	Phase 2

Detailed Description

The purpose of this study is to test the effectiveness and safety of Gemcitabine and Pazopanib compared with Gemcitabine and Docetaxel in participants with soft tissue sarcoma. Screening tests will be done to ensure subjects are eligible to participate in this study. If the exams, tests and procedures show that subjects can be in the study, and they choose to take part, then they will be "randomized" into one of the two study groups: Group 1 or Group 2. Subjects in Group 1 will receive Gemcitabine 1000 mg/m2 intravenously (directly into a vein) on Day 1 and Day 8 and Pazopanib 800mg by mouth daily. Subjects in Group 2 will receive Gemcitabine 900 mg/m2 intravenously on Day 1 and Day 8 and Docetaxel 100 mg/m2 intravenously on Day 8. Both groups will be in 21 day cycles. Both groups will be asked to complete "quality of life" questionnaires, on their first visit, then at 6 weeks (2nd cycle), 18 weeks (6th cycle) and at the end of study treatment. Subjects will be followed for up to 2 years.

Study Design

• Study Type: Interventional
• Actual Enrollment: 90 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Randomized, Open-label, Phase II, Multi-center Trial of Gemcitabine (G) With Pazopanib (P) or Gemcitabine (G) With Docetaxel (T) in Previously Treated Subjects With Advanced Soft Tissue Sarcoma
• Actual Study Start Date: Sep 27, 2012
• Actual Primary Completion Date: Apr 24, 2019
• Actual Study Completion Date: Apr 24, 2019

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Experimental Patients in Group 1 will get Gemcitabine 1000 mg/m2 intravenously on Day 1 and Day 8 and Pazopanib 800mg by mouth daily on a 21 day cycle. Cycles will continue until disease progression or patient withdrawal.	Drug: Gemcitabine and Pazopanib; Gemcitabine 1000 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Pazopanib 800 mg by oral tablet daily for a 21 day cycle.
Active Comparator: Standard of Care Patients in Group 2 will get Gemcitabine 900 mg/m2 intravenously on Day 1 and Day 8. Additionally on Day 8, patients will have Docetaxel 100 mg/m2 given intravenously. on a 21 day cycle. If disease progression occurs on this treatment, patients will have the option to receive treatment with Gemcitabine and Pazopanib (group 1).	Drug: Gemcitabine and Docetaxel; Gemcitabine 900 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Docetaxel 100 mg/m2 by IV on day 8 of a 21 day cycle.

Outcome Measures

Primary Outcome Measures

1. Average Number of Months of Progression-free Survival [minimum of 18 months]

   To estimate the PFS of the combination of G+P or G+T in patients with metastatic and/or locally advanced or recurrent STS. Progression free survival is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.

2. Rate of Participants With Grade 3 or Higher Toxicity [30 days post end of treatment]

   Toxicity is graded according to the CTCAE v 4.

Secondary Outcome Measures

1. Hazard Ratio [minimum of 18 months]

   Hazard ratio is defined as the rate of survival in the experimental group versus the standard of care group. A hazard ratio of greater than one or less than one means that survival was better in one of the groups.

2. Average Score of Quality of Life [Baseline, Cycle 2, Cycle 6 and End of Treatment]

   To estimate the quality of life of patient with metastatic an/or locally advanced recurrent STS using the Quality of Life Questionnaire (QLQ-C30). The QLQ-C30 is scored on a scale from 0-100 with "0" indicating "never" and "100" indicating "always" in regard the the participants' experience of fatigue, nausea/vomiting, pain, disponae, insomnia, appetite loss, constipation, diarrhea, financial concerns at 4 time points through the study.

3. Response Rate [minimum of 18 months]

   Response rate is defined as follows: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

• Subjects must provide written informed consent prior to performance of study-specific procedures or assessments, and must be willing to comply with treatment and follow up. Procedures conducted as part of the subject's routine clinical management (e.g., blood count, imaging study) and obtained prior to signing of informed consent may be utilized for screening or baseline purposes provided these procedures are conducted as specified in the protocol.

• Age ≥ 18 years or legal age of consent if greater than 18 years.

• Histologically or cytologically confirmed diagnosis of sarcoma of soft tissue. (Patients with liposarcoma, bone sarcoma or GIST will be excluded).

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

• Subjects must have metastatic and/or locally advanced or locally recurrent disease that is not amenable to curative surgical resection.

• A minimum of 1 and a maximum of 3 prior chemotherapy regimens for recurrent/metastatic disease. Patients eligible for an anthracycline should have received a prior anthracycline containing regimen. Patients who decline or are not eligible for anthracycline treatment may be considered for this protocol as a first line treatment.

• Patients must have measurable disease by RECIST 1.1. or cutaneous disease amenable to serial measurements should be present. Measurable disease (a 'target' lesion) is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be ≥ 10 mm when measured by CT (CT scan slice thickness no greater than 5 mm); ≥ 10 mm caliper measurement by clinical exam (lesions which cannot be accurately measured with calipers should be recorded as non-measurable); and ≥ 20 mm by chest x-ray.

• Able to swallow and retain oral medication.

• Adequate organ system function

• A female is eligible to enter and participate in this study if she is of:

• Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who has had:

• A hysterectomy

• A bilateral oophorectomy (ovariectomy)

• A bilateral tubal ligation

• Is post-menopausal

Subjects not using hormone replacement therapy (HRT) must have experienced total cessation of menses for ≥ 1 year and be greater than 45 years in age, OR, in questionable cases, have a follicle stimulating hormone (FSH) value > 40 mIU/mL and an estradiol value < 40pg/mL (< 140 pmol/L).

Subjects using HRT must have experienced total cessation of menses for >= 1 year and be greater than 45 years of age OR have had documented evidence of menopause based on FSH and estradiol concentrations prior to initiation of HRT.

-- Childbearing potential, including any female who has had a negative serum pregnancy test within 2 weeks prior to the first dose of study treatment, preferably as close to the first dose as possible, and agrees to use adequate contraception. Acceptable contraceptive methods, when used consistently and in accordance with both the product label and the instructions of the physician, are as follow:

• Complete abstinence from sexual intercourse for 14 days before exposure to investigational product, through the dosing period, and for at least 21 days after the last dose of investigational product

• Oral contraceptive, either combined or progestogen alone

• Injectable progestogen

• Implants of levonorgestrel

• Estrogenic vaginal ring

• Percutaneous contraceptive patches

• Intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year

• Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject

• Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository)

Female subjects who are lactating should discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period and for 14 days following the last dose of study drug.

Exclusion Criteria

• Prior therapy with pazopanib, gemcitabine or docetaxel.

• Any concern for hypersensitivity to pazopanib, gemcitabine or docetaxel.

• Prior malignancy. Note: Subjects who have had another malignancy and have been disease-free for 3 years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible.

• History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for 6 months prior to first dose of study drug. Screening with CNS imaging studies (computed tomography [CT] or magnetic resonance imaging [MRI]) is required only if clinically indicated or if the subject has a history of CNS metastases.

• Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to:

• Active peptic ulcer disease

• Known intraluminal metastatic lesion/s with risk of bleeding

• Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other gastrointestinal conditions with increased risk of perforation

• History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess within 28 days prior to beginning study treatment.

Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:

• Malabsorption syndrome

• Major resection of the stomach or small bowel and experiencing the "dumping" syndrome.

• Presence of uncontrolled infection.

• Prior mediastinal radiation

• Corrected QT interval (QTc) > 480 msecs using Bazett's formula.

• History of any one or more of the following conditions within the past 6 months:

• Cardiac angioplasty or stenting

• Myocardial infarction

• Unstable angina

• Coronary artery bypass graft surgery

• Symptomatic peripheral vascular disease

• Pneumonitis

• Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA) (Appendix D).

• Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ≥ 150 mmHg or diastolic blood pressure (DBP) of ≥ 90mmHg].

Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. BP must be re-assessed on two occasions that are separated by a minimum of 1 hour; on each of these occasions, the mean (of 3 readings) SBP/DBP values from each BP assessment must be < 150/90 mmHg in order for a subject to be eligible for the study.

-History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.

Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks prior to registration and are fully anti-coagulated are eligible.

• Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major).

• Evidence of active bleeding or bleeding diathesis.

• Known endobronchial lesions and/or lesions infiltrating major pulmonary Hemoptysis in excess of 2.5 mL (or one half teaspoon) within 8 weeks of first dose of study drug.

• Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.

• Unable or unwilling to discontinue use of prohibited medications listed in Section 5.2.3 for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the study.

• Treatment with any of the following anti-cancer or non-oncologic investigational therapies:

• radiation therapy, surgery or tumor embolization within 14 days prior to registration.

• chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days or 2.5 half-lives of a drug (whichever is longer) prior to registration.

• non-oncologic investigational products within 30 days or 5 halflives, whichever is longer.

• Any ongoing toxicity from prior anti-cancer therapy that is >Grade 1 and/or that is progressing in severity, except alopecia.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	The University of Arizona Cancer Center	Tucson	Arizona	United States
2	University of Colorado Cancer Center	Aurora	Colorado	United States	80045
3	Emory University	Atlanta	Georgia	United States	30322
4	University of Iowa Hospitals & Clinics	Iowa City	Iowa	United States
5	Johns Hopkins University	Baltimore	Maryland	United States	21218
6	University of Michigan	Ann Arbor	Michigan	United States	48109
7	Washington University at St. Louis	Saint Louis	Missouri	United States	63130
8	University of Texas MD Anderson Cancer Center	Houston	Texas	United States	77030

Sponsors and Collaborators

• Medical University of South Carolina
• Novartis

Investigators

• Principal Investigator: Daniel Y. Reuben, MD, Medical University of South Carolina Hollings Cancer Center

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - Aug 11, 2016

More Information

Publications

• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266.
• Xin G, Wang M, Jiao LL, Xu GB, Wang HY. Protein-to-creatinine ratio in spot urine samples as a predictor of quantitation of proteinuria. Clin Chim Acta. 2004 Dec;350(1-2):35-9.

• Responsible Party: Medical University of South Carolina
• ClinicalTrials.gov Identifier: NCT01593748
• Other Study ID Numbers: 101644; PAZ115785; CPZP034BUS1T
• First Posted: May 8, 2012
• Last Update Posted: Apr 6, 2020
• Last Verified: Mar 1, 2020

• Keywords provided by Medical University of South Carolina: Sarcoma; Soft Tissue Sarcoma
• Additional relevant MeSH terms: Sarcoma; Gemcitabine; Docetaxel

Study Results

Participant Flow

Arm/Group Title	Experimental	Standard of Care
Arm/Group Description	Patients in Group 1 will get Gemcitabine 1000 mg/m2 intravenously on Day 1 and Day 8 and Pazopanib 800mg by mouth daily on a 21 day cycle. Cycles will continue until disease progression or patient withdrawal. Gemcitabine and Pazopanib: Gemcitabine 1000 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Pazopanib 800 mg by oral tablet daily for a 21 day cycle.	Patients in Group 2 will get Gemcitabine 900 mg/m2 intravenously on Day 1 and Day 8. Additionally on Day 8, patients will have Docetaxel 100 mg/m2 given intravenously. on a 21 day cycle. If disease progression occurs on this treatment, patients will have the option to receive treatment with Gemcitabine and Pazopanib (group 1). Gemcitabine and Docetaxel: Gemcitabine 900 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Docetaxel 100 mg/m2 by IV on day 8 of a 21 day cycle.
Period Title: Overall Study
STARTED	45	45
COMPLETED	45	45
NOT COMPLETED	0	0

Baseline Characteristics

Arm/Group Title	Experimental	Standard of Care	Total
Arm/Group Description	Patients in Group 1 will get Gemcitabine 1000 mg/m2 intravenously on Day 1 and Day 8 and Pazopanib 800mg by mouth daily on a 21 day cycle. Cycles will continue until disease progression or patient withdrawal. Gemcitabine and Pazopanib: Gemcitabine 1000 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Pazopanib 800 mg by oral tablet daily for a 21 day cycle.	Patients in Group 2 will get Gemcitabine 900 mg/m2 intravenously on Day 1 and Day 8. Additionally on Day 8, patients will have Docetaxel 100 mg/m2 given intravenously. on a 21 day cycle. If disease progression occurs on this treatment, patients will have the option to receive treatment with Gemcitabine and Pazopanib (group 1). Gemcitabine and Docetaxel: Gemcitabine 900 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Docetaxel 100 mg/m2 by IV on day 8 of a 21 day cycle.	Total of all reporting groups
Overall Participants	45	45	90
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	57.93 (13.76)	54.6 (14.10)	56.27 (13.95)
Sex: Female, Male (Count of Participants)
Female	24 53.3%	22 48.9%	46 51.1%
Male	21 46.7%	23 51.1%	44 48.9%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	4 8.9%	2 4.4%	6 6.7%
Not Hispanic or Latino	37 82.2%	43 95.6%	80 88.9%
Unknown or Not Reported	4 8.9%	0 0%	4 4.4%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%	0 0%	0 0%
Asian	0 0%	2 4.4%	2 2.2%
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%
Black or African American	3 6.7%	8 17.8%	11 12.2%
White	36 80%	33 73.3%	69 76.7%
More than one race	2 4.4%	2 4.4%	4 4.4%
Unknown or Not Reported	4 8.9%	0 0%	4 4.4%

Outcome Measures

1. Primary Outcome

Title	Average Number of Months of Progression-free Survival
Description	To estimate the PFS of the combination of G+P or G+T in patients with metastatic and/or locally advanced or recurrent STS. Progression free survival is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.
Time Frame	minimum of 18 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Experimental	Standard of Care
Arm/Group Description	Patients in Group 1 will get Gemcitabine 1000 mg/m2 intravenously on Day 1 and Day 8 and Pazopanib 800mg by mouth daily on a 21 day cycle. Cycles will continue until disease progression or patient withdrawal. Gemcitabine and Pazopanib: Gemcitabine 1000 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Pazopanib 800 mg by oral tablet daily for a 21 day cycle.	Patients in Group 2 will get Gemcitabine 900 mg/m2 intravenously on Day 1 and Day 8. Additionally on Day 8, patients will have Docetaxel 100 mg/m2 given intravenously. on a 21 day cycle. If disease progression occurs on this treatment, patients will have the option to receive treatment with Gemcitabine and Pazopanib (group 1). Gemcitabine and Docetaxel: Gemcitabine 900 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Docetaxel 100 mg/m2 by IV on day 8 of a 21 day cycle.
Measure Participants	45	45
Median (95% Confidence Interval) [months]	4.1	4.1

2. Primary Outcome

Title	Rate of Participants With Grade 3 or Higher Toxicity
Description	Toxicity is graded according to the CTCAE v 4.
Time Frame	30 days post end of treatment

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Experimental	Standard of Care
Arm/Group Description	Patients in Group 1 will get Gemcitabine 1000 mg/m2 intravenously on Day 1 and Day 8 and Pazopanib 800mg by mouth daily on a 21 day cycle. Cycles will continue until disease progression or patient withdrawal. Gemcitabine and Pazopanib: Gemcitabine 1000 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Pazopanib 800 mg by oral tablet daily for a 21 day cycle.	Patients in Group 2 will get Gemcitabine 900 mg/m2 intravenously on Day 1 and Day 8. Additionally on Day 8, patients will have Docetaxel 100 mg/m2 given intravenously. on a 21 day cycle. If disease progression occurs on this treatment, patients will have the option to receive treatment with Gemcitabine and Pazopanib (group 1). Gemcitabine and Docetaxel: Gemcitabine 900 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Docetaxel 100 mg/m2 by IV on day 8 of a 21 day cycle.
Measure Participants	45	45
Count of Participants [Participants]	39 86.7%	39 86.7%

3. Secondary Outcome

Title	Hazard Ratio
Description	Hazard ratio is defined as the rate of survival in the experimental group versus the standard of care group. A hazard ratio of greater than one or less than one means that survival was better in one of the groups.
Time Frame	minimum of 18 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Experimental	Standard of Care
Arm/Group Description	Patients in Group 1 will get Gemcitabine 1000 mg/m2 intravenously on Day 1 and Day 8 and Pazopanib 800mg by mouth daily on a 21 day cycle. Cycles will continue until disease progression or patient withdrawal. Gemcitabine and Pazopanib: Gemcitabine 1000 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Pazopanib 800 mg by oral tablet daily for a 21 day cycle.	Patients in Group 2 will get Gemcitabine 900 mg/m2 intravenously on Day 1 and Day 8. Additionally on Day 8, patients will have Docetaxel 100 mg/m2 given intravenously. on a 21 day cycle. If disease progression occurs on this treatment, patients will have the option to receive treatment with Gemcitabine and Pazopanib (group 1). Gemcitabine and Docetaxel: Gemcitabine 900 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Docetaxel 100 mg/m2 by IV on day 8 of a 21 day cycle.
Measure Participants	45	45
Number (95% Confidence Interval) [hazard ratio]	1.2	NA

4. Secondary Outcome

Title	Average Score of Quality of Life
Description	To estimate the quality of life of patient with metastatic an/or locally advanced recurrent STS using the Quality of Life Questionnaire (QLQ-C30). The QLQ-C30 is scored on a scale from 0-100 with "0" indicating "never" and "100" indicating "always" in regard the the participants' experience of fatigue, nausea/vomiting, pain, disponae, insomnia, appetite loss, constipation, diarrhea, financial concerns at 4 time points through the study.
Time Frame	Baseline, Cycle 2, Cycle 6 and End of Treatment

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Experimental	Standard of Care
Arm/Group Description	Patients in Group 1 will get Gemcitabine 1000 mg/m2 intravenously on Day 1 and Day 8 and Pazopanib 800mg by mouth daily on a 21 day cycle. Cycles will continue until disease progression or patient withdrawal. Gemcitabine and Pazopanib: Gemcitabine 1000 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Pazopanib 800 mg by oral tablet daily for a 21 day cycle.	Patients in Group 2 will get Gemcitabine 900 mg/m2 intravenously on Day 1 and Day 8. Additionally on Day 8, patients will have Docetaxel 100 mg/m2 given intravenously. on a 21 day cycle. If disease progression occurs on this treatment, patients will have the option to receive treatment with Gemcitabine and Pazopanib (group 1). Gemcitabine and Docetaxel: Gemcitabine 900 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Docetaxel 100 mg/m2 by IV on day 8 of a 21 day cycle.
Measure Participants	45	45
Fatigue at baseline	61.79 (27.89)	67.12 (23.44)
Nausea/Vommiting at baseline	91.06 (14.48)	90.99 (16.94)
Pain at baseline	61.38 (32.80)	74.77 (25.65)
Dysponae at baseline	22.76 (32.86)	21.62 (29.62)
Insomnia at baseline	45.53 (39.97)	36.04 (30.81)
Appetite loss at baseline	22.76 (32.01)	15.32 (26.75)
Constipation at baseline	14.63 (26.92)	15.32 (23.03)
Diarrhea at baseline	4.88 (11.93)	8.11 (16.49)
Financial at baseline	37.40 (40.96)	32.43 (34.68)
Fatigue at cycle 2	52.89 (23.85)	55.09 (25.06)
Nausea/Vomitting at cycle 2	80.67 (17.13)	93.75 (9.60)
Pain at cycle 2	66.00 (26.56)	83.33 (20.85)
Dyspnoae at cycle 2	24.00 (24.57)	26.39 (24.04)
Insomnia at cycle 2	42.67 (34.05)	38.89 (28.94)
Appetite loss at cycle 2	36.11 (32.48)	26.39 (32.57)
Constipation at cycle 2	13.33 (21.52)	23.61 (25.02)
Diarrhea at cycle 2	4.88 (11.93)	8.11 (16.49)
Financial at cycle 2	26.67 (34.69)	22.22 (27.22)
Fatigue at cycle 6	64.44 (11.48)	51.11 (30.63)
Nausea/vommiting at cycle 6	86.67 (7.03)	8.05 (95.00)
Pain at cycle 6	80.00 (23.31)	78.33 (30.48)
Dyspnoae at cycle 6	10.00 (16.10)	43.33 (22.50)
Insomnia at cycle 6	23.33 (16.10)	33.33 (27.22)
Appetite loss at cycle 6	26.67 (34.43)	30.00 (24.60)
Constipation at cycle 6	13.33 (17.21)	13.33 (23.31)
Diarrhea at cycle 6	36.67 (24.60)	20.00 (23.31)
Financial at cycle 6	23.33 (31.62)	20.00 (23.31)
Fatigue at end of study	49.81 (22.74)	49.77 (25.77)
Nausea/vomitting at end of study	75.86 (23.82)	92.36 (12.02)
Pain at end of study	53.45 (32.85)	72.92 (24.48)
Dysponae at end of study	31.03 (33.25)	34.72 (28.62)
Insomnia at end of study	48.28 (36.28)	37.50 (26.58)
Appetite loss at end of study	37.93 (33.00)	23.61 (28.62)
Constipation at end of study	17.24 (24.59)	29.17 (30.00)
Diarrhea at end of study	21.43 (22.62)	15.28 (24.04)
Financial at end of study	39.60 (39.29)	29.17 (33.06)

5. Secondary Outcome

Title	Response Rate
Description	Response rate is defined as follows: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study
Time Frame	minimum of 18 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Experimental	Standard of Care
Arm/Group Description	Patients in Group 1 will get Gemcitabine 1000 mg/m2 intravenously on Day 1 and Day 8 and Pazopanib 800mg by mouth daily on a 21 day cycle. Cycles will continue until disease progression or patient withdrawal. Gemcitabine and Pazopanib: Gemcitabine 1000 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Pazopanib 800 mg by oral tablet daily for a 21 day cycle.	Patients in Group 2 will get Gemcitabine 900 mg/m2 intravenously on Day 1 and Day 8. Additionally on Day 8, patients will have Docetaxel 100 mg/m2 given intravenously. on a 21 day cycle. If disease progression occurs on this treatment, patients will have the option to receive treatment with Gemcitabine and Pazopanib (group 1). Gemcitabine and Docetaxel: Gemcitabine 900 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Docetaxel 100 mg/m2 by IV on day 8 of a 21 day cycle.
Measure Participants	43	45
Complete Response	0 0%	0 0%
Partial Response	5 11.1%	8 17.8%
Stable Disease	24 53.3%	21 46.7%
Progressive Disease	14 31.1%	16 35.6%

Adverse Events

Time Frame	study enrollment to 30 days from last treatment; inclusive of crossover treatment
Adverse Event Reporting Description	AE data was collected from subjects at every clinic visit and day 1 of every cycle.
Arm/Group Title	Experimental		Standard of Care
Arm/Group Description	Patients in Group 1 will get Gemcitabine 1000 mg/m2 intravenously on Day 1 and Day 8 and Pazopanib 800mg by mouth daily on a 21 day cycle. Cycles will continue until disease progression or patient withdrawal. Gemcitabine and Pazopanib: Gemcitabine 1000 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Pazopanib 800 mg by oral tablet daily for a 21 day cycle.		Patients in Group 2 will get Gemcitabine 900 mg/m2 intravenously on Day 1 and Day 8. Additionally on Day 8, patients will have Docetaxel 100 mg/m2 given intravenously. on a 21 day cycle. If disease progression occurs on this treatment, patients will have the option to receive treatment with Gemcitabine and Pazopanib (group 1). Gemcitabine and Docetaxel: Gemcitabine 900 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Docetaxel 100 mg/m2 by IV on day 8 of a 21 day cycle.
All Cause Mortality
	Experimental		Standard of Care
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	32/45 (71.1%)		30/45 (66.7%)
Serious Adverse Events
	Experimental		Standard of Care
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	28/45 (62.2%)		31/45 (68.9%)
Blood and lymphatic system disorders
Febrile Neutropenia	0/45 (0%)		2/45 (4.4%)
Anemia	0/45 (0%)		1/45 (2.2%)
Cardiac disorders
Asystole	1/45 (2.2%)		0/45 (0%)
Atrial Fibrilation	1/45 (2.2%)		1/45 (2.2%)
Heart Failure	1/45 (2.2%)		0/45 (0%)
Pericardial Tamponade	1/45 (2.2%)		1/45 (2.2%)
Supraventricular Tachycardia	0/45 (0%)		1/45 (2.2%)
Gastrointestinal disorders
Nausea	2/45 (4.4%)		0/45 (0%)
Pancreatitis	2/45 (4.4%)		0/45 (0%)
Vomiting	2/45 (4.4%)		1/45 (2.2%)
Ascites	1/45 (2.2%)		0/45 (0%)
General disorders
Fever	3/45 (6.7%)		3/45 (6.7%)
Pain	1/45 (2.2%)		1/45 (2.2%)
Edema Limbs	0/45 (0%)		2/45 (4.4%)
Edema Trunk	0/45 (0%)		1/45 (2.2%)
Fatigue	0/45 (0%)		2/45 (4.4%)
Infections and infestations
Bacterial Infection	1/45 (2.2%)		0/45 (0%)
Lung Infection	0/45 (0%)		1/45 (2.2%)
Sepsis	0/45 (0%)		2/45 (4.4%)
Other Infection	1/45 (2.2%)		0/45 (0%)
Injury, poisoning and procedural complications
Spinal Fracture	1/45 (2.2%)		0/45 (0%)
Vascular Access Complication	1/45 (2.2%)		0/45 (0%)
Fracture	0/45 (0%)		1/45 (2.2%)
Investigations
Platelet Count Decrease	2/45 (4.4%)		2/45 (4.4%)
Alanine Aminotransferase Increased	1/45 (2.2%)		0/45 (0%)
Metabolism and nutrition disorders
Dehydration	0/45 (0%)		1/45 (2.2%)
Musculoskeletal and connective tissue disorders
Back Pain	0/45 (0%)		1/45 (2.2%)
Bone Pain/Right leg	0/45 (0%)		1/45 (2.2%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bleeding from Tumor	1/45 (2.2%)		0/45 (0%)
Nervous system disorders
Ischemia Cerebrovascular	1/45 (2.2%)		0/45 (0%)
Respiratory, thoracic and mediastinal disorders
Respiratory Failure	1/45 (2.2%)		2/45 (4.4%)
Dyspnea	1/45 (2.2%)		1/45 (2.2%)
Hypoxia	0/45 (0%)		1/45 (2.2%)
Pneumonitis	0/45 (0%)		1/45 (2.2%)
Acute Left Lung Pneumonia/Infection	1/45 (2.2%)		0/45 (0%)
Vascular disorders
Hypotension	0/45 (0%)		1/45 (2.2%)
Thromboembolic Event	1/45 (2.2%)		0/45 (0%)
Other (Not Including Serious) Adverse Events
	Experimental		Standard of Care
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	45/45 (100%)		45/45 (100%)
Blood and lymphatic system disorders
Anemia	27/45 (60%)		32/45 (71.1%)
Gastrointestinal disorders
Nausea	31/45 (68.9%)		18/45 (40%)
Constipation	13/45 (28.9%)		19/45 (42.2%)
Vomiting	25/45 (55.6%)		5/45 (11.1%)
Diarrhea	22/45 (48.9%)		14/45 (31.1%)
Mucositis Oral	7/45 (15.6%)		11/45 (24.4%)
Abdominal Pain	7/45 (15.6%)		5/45 (11.1%)
General disorders
Fatigue	34/45 (75.6%)		28/45 (62.2%)
Edema Limbs	7/45 (15.6%)		16/45 (35.6%)
Pain	16/45 (35.6%)		16/45 (35.6%)
Fever	8/45 (17.8%)		11/45 (24.4%)
Noncardiac Chest Pain	5/45 (11.1%)		2/45 (4.4%)
Investigations
Platelet Count Decreased	34/45 (75.6%)		33/45 (73.3%)
Neutrophil Count Decreased	26/45 (57.8%)		11/45 (24.4%)
Alanine Aminotransferase Increased	20/45 (44.4%)		12/45 (26.7%)
White Blood Cell Decreased	19/45 (42.2%)		13/45 (28.9%)
Aspartate Aminotransferase Increased	20/45 (44.4%)		12/45 (26.7%)
Alkaline Phosphatase Increased	13/45 (28.9%)		10/45 (22.2%)
Lymphocyte Count Decreased	9/45 (20%)		10/45 (22.2%)
Creatinine Increased	2/45 (4.4%)		5/45 (11.1%)
Blood Bilirubin Increased	6/45 (13.3%)		2/45 (4.4%)
Metabolism and nutrition disorders
Anorexia	16/45 (35.6%)		13/45 (28.9%)
Hyperglycemia	12/45 (26.7%)		13/45 (28.9%)
Hypokalemia	7/45 (15.6%)		11/45 (24.4%)
Hypoalbuminemia	5/45 (11.1%)		9/45 (20%)
Hyponatremia	6/45 (13.3%)		9/45 (20%)
Hypocalcemia	3/45 (6.7%)		7/45 (15.6%)
Hypernatremia	3/45 (6.7%)		5/45 (11.1%)
Hypomagnesemia	0/45 (0%)		5/45 (11.1%)
Musculoskeletal and connective tissue disorders
Myalgia	3/45 (6.7%)		12/45 (26.7%)
Bone Pain	2/45 (4.4%)		7/45 (15.6%)
Generalized Muscle Weakness	2/45 (4.4%)		5/45 (11.1%)
Pain In Extremity	5/45 (11.1%)		3/45 (6.7%)
Nervous system disorders
Dysgeusia	5/45 (11.1%)		12/45 (26.7%)
Peripheral Sensory Neuropathy	0/45 (0%)		11/45 (24.4%)
Headache	15/45 (33.3%)		10/45 (22.2%)
Dizziness	7/45 (15.6%)		6/45 (13.3%)
Psychiatric disorders
Insomnia	9/45 (20%)		7/45 (15.6%)
Depression	0/45 (0%)		5/45 (11.1%)
Respiratory, thoracic and mediastinal disorders
Dyspnea	10/45 (22.2%)		14/45 (31.1%)
Cough	9/45 (20%)		12/45 (26.7%)
Epistaxis	9/45 (20%)		8/45 (17.8%)
Hoarseness	7/45 (15.6%)		0/45 (0%)
Skin and subcutaneous tissue disorders
Alopecia	3/45 (6.7%)		8/45 (17.8%)
Nail Discoloration	0/45 (0%)		6/45 (13.3%)
Palmarplantar Erythrodysesthesia Syndrome	5/45 (11.1%)		5/45 (11.1%)
Vascular disorders
Hypertension	16/45 (35.6%)		3/45 (6.7%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.